FAM65A as a novel prognostic biomarker in human tumors reveal by a pan-cancer analysis

Abstract

Background Family with sequence similarity 65 member A (FAM65A), also known as RIPOR1, is differentially expressed between human tumor and non-tumor tissues in kinds of cancers. In addition, it was reported that the product of FAM65A may be a biomarker for cholangiocarcinoma patients. However, there is still no evidence on the relationship between the FAM65A and different types of tumors. Our study is mainly for exploring the prognostic values of FAM65A in pan-cancer and for further discovering a potential therapeutics target. Methods We analyzed FAM65A expression, prognostic values, genetic alteration, protein phosphorylation, immune infiltration and enrichment analysis across different types of human malignant tumors based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Additionally, Real-Time PCR (RT-qPCR) was performed to further confirm the roles of FAM65A in the pathogenesis of colorectal cancer. Results We found that FAM65A expression was associated with the prognosis of multiple human tumors, especially colorectal cancer. Moreover, we also observed that FAM65A was highly expressed in colorectal cancer through RT-qPCR. We observed that decreasing phosphorylation level of the S351 locus in colon adenocarcinoma, uterine corpus endometrial carcinoma and lung adenocarcinoma. And the expression of FAM65A was positively related to cancer-associated fibroblasts (CAFs) infiltration in many tumors, such as colon adenocarcinoma. Therefore, FAM65A may be a potential prognostic biomarker of human tumors.

Discovering Breast Cancer Biomarkers Candidates through mRNA Expression Analysis Based on The Cancer Genome Atlas Database

“…Recently, research on the discovery of tumor biomarkers based on big data analysis is actively being conducted, such as the use of TCGA data to identify these biomarkers [ 13 , 14 , 15 , 16 ]. Online bioinformatics tools contain big data that provide comprehensive genetic information for various cancers via microarray and next-generation sequencing technology [ 10 , 11 ].…”

“…In addition, many research results have been published in tumor research other than that of breast cancer. In the case of cholangiocarcinoma, the cluster of differentiation 247, Fc gamma receptor Ia, and transformation/transcription-domain-associated proteins were suggested as new markers for mRNA-based cancer vaccine targets, and significance with a high expression of the family with sequence similarity 65 member A was also reported in colorectal cancer [ 15 , 16 ]. Generally, TCGA data-based analysis is considered to increase biological insight by studying the tumor environment based on a vast amount of analysis.…”

Gene expression in organoids: an expanding horizon

“…Multi-omics allow global genetic, epigenetic, gene expression, and metabolic analyses. For instance, recent pancancer [ 56 , 57 ] multi-omics studies have unveiled new putative targets for cancer therapy [ 58 , 59 ]. In this review, we will focus on gene expression and its regulation on organoids as a research model, we will describe recent advances of sequencing techniques, and we will outline future direction in organoid research.…”

Multi‑dimensional analysis reveals NCKAP5L is a promising biomarker for the diagnosis and prognosis of human cancers, especially colorectal cancer

“…Consequently, a wealth of sequencing and clinical data for different types of cancer is now available (5). By using public databases such as The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), bioinformatics can be used to perform pan-cancer analysis at the DNA, RNA, protein and epigenetic level to reveal the roles of genes in different cancers (6)(7)(8)(9).…”